<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic total occlusion (CTO) in the coronary circulation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic total occlusion (CTO) in the coronary circulation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic total occlusion (CTO) in the coronary circulation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Yeh, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hector Tamez, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H459766368"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients referred for coronary angiography are frequently found to have CTO of one or more coronary arteries. CTO may occur in isolation or in conjunction with important stenoses in other coronary arteries. For these patients, most of whom have failed medical therapy for angina management, there is uncertainty of the benefit of percutaneous coronary intervention (PCI) for CTO, and there are significant technical complexities and lower success rates with the procedure. </p><p>This topic will give our approach to issues surrounding the use of PCI for CTO in patients with stable angina pectoris and who have unacceptable symptoms while receiving maximal medical therapy. (See  <a class="medical medical_review" href="/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a> and  <a class="medical medical_review" href="/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H204765279"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>CTO is defined as a 100 percent stenosis of a coronary artery with Thrombolysis In Myocardial Infarction (TIMI) 0 flow  (<a class="graphic graphic_table graphicRef51941" href="/d/graphic/51941.html" rel="external">table 1</a>) for more than three months (based on angiography or symptoms) [<a href="#rid1">1</a>]. Severe (but not total) occlusions with impaired flow are often referred to as "functional" CTOs, but such lesions are often technically less challenging to address percutaneously given the presence of an antegrade channel [<a href="#rid2">2</a>]. This topic will focus on "true" CTOs.</p><p>A broad group of experts from North America and Europe, including academicians, researchers, and practicing physicians, comprise the Coronary Artery Chronic Total Occlusion Academic Research Consortium. They released a consensus recommendations document in early 2021; it includes procedural definitions among other components [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H936019824"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>CTOs are highly prevalent among patients undergoing diagnostic coronary angiography, where they are found in roughly one-quarter to one-third of patients, though the prevalence is related to the group studied [<a href="#rid4">4-8</a>]. Patients with a history of coronary artery bypass graft surgery are found to have CTOs of their native vessels more frequently (54 percent), while patients presenting with ST-elevation myocardial infarction (STEMI) are less likely to have a CTO (10 percent) [<a href="#rid5">5,9</a>]. (See  <a class="medical medical_review" href="/d/html/72.html" rel="external">"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome"</a> and  <a class="medical medical_review" href="/d/html/103273.html" rel="external">"Acute coronary syndromes: Approach to nonculprit lesions"</a> and  <a class="medical medical_review" href="/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management"</a>.)</p><p>The right coronary artery is more frequently (55 to 65 percent) involved than the left anterior descending or circumflex arteries [<a href="#rid8">8,10</a>].</p><p class="headingAnchor" id="H2736190900"><span class="h1">INDICATIONS FOR CORONARY INTERVENTION</span><span class="headingEndMark"> — </span>We recommend percutaneous coronary intervention (PCI) for two groups of patients who are receiving optimal medical therapy: those for whom coronary artery bypass graft surgery offers a survival advantage but who cannot undergo this form of revascularization, and those who are dissatisfied with their quality of life due to symptoms or medication side effects. In patients who do not meet either criterion, we recommend a trial of optimal medical therapy prior to considering PCI. (See  <a class="medical medical_review" href="/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization", section on 'Indications'</a>.)</p><p>High-quality evidence to suggest that CTO PCI can improve survival does not exist. Thus, the principal indication is to improve symptoms [<a href="#rid11">11,12</a>]. </p><p class="headingAnchor" id="H1018346699"><span class="h1">CLINICAL ASSOCIATIONS</span><span class="headingEndMark"> — </span>CTO is most often diagnosed in patients referred for coronary angiography and possible revascularization due to angina refractory to medical therapy or diagnostic testing suggestive of myocardial ischemia. In addition to causing symptoms, CTOs are associated with a worse overall prognosis, with higher rates of death and non-fatal adverse cardiovascular events in several populations. Patients with CTOs tend to be older and have more comorbidities and greater impairment of left ventricular function [<a href="#rid4">4-6</a>]. Furthermore, patients with unrevascularized CTOs have been found to have higher mortality (adjusted hazard ratio [HR] 1.35; 95% CI 1.14-1.59) and a higher risk of major adverse cardiovascular events (MACE) including death and myocardial infarction (adjusted HR 1.14; 95% CI 0.92-1.41) compared with patients with multivessel coronary artery disease who are completely revascularized [<a href="#rid13">13,14</a>].</p><p>With regard to patients with acute coronary syndrome (ACS), most studies have excluded patients with CTO. The following observations have been made:</p><p class="bulletIndent1"><span class="glyph">●</span>The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial included patients who presented with non ST-elevation ACS who had a CTO as a nonculprit lesion and showed that those patients had higher MACE at one year as compared with those who were completely revascularized (25.9 versus 22.2 percent, respectively) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An analysis of the HORIZONS-AMI study showed higher three-year mortality in patients who present with STEMI and three-vessel disease with at least one CTO as compared with patients with STEMI with three-vessel coronary artery disease without CTO (19.4 versus 7 percent; HR 2.97; 95% CI 1.84-4.8) [<a href="#rid9">9</a>]. Patients who present with STEMI and a CTO in a non-infarct-related artery have higher 30-day mortality (HR 3.6; 95% CI 2.6 to 4.7) [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H3175132603"><span class="h1">PREPROCEDURAL STEPS</span><span class="headingEndMark"> — </span>Prior to percutaneous coronary intervention (PCI), we review the indication for revascularization, choose between PCI or coronary artery bypass graft surgery (CABG), and have a full discussion with the patient of the benefits and risks.</p><p class="headingAnchor" id="H879053830"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Stable angina or anginal equivalent (such dyspnea on exertion) refractory to optimal medical therapy, as well as the presence of a large ischemic area, are the most common indications for consideration of revascularization for CTO [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization"</a>.)</p><p>In addition, there should be a reasonable likelihood of success with an acceptable degree of risk.</p><p class="headingAnchor" id="H2408030063"><span class="h2">Percutaneous coronary intervention versus coronary artery bypass graft surgery</span><span class="headingEndMark"> — </span>In patients who meet usual criteria for referral for CABG, the presence of CTO does not influence that decision. (See  <a class="medical medical_review" href="/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Our approach'</a>.) </p><p>In CTO patients who otherwise meet criteria for PCI, such as those with single-vessel disease, our choice between PCI and CABG is determined in part by which coronary artery includes the CTO.</p><p>We favor PCI over CABG in patients who have single-vessel disease of the right or left circumflex coronary artery, as well as those who have had a prior CABG with a patent left internal mammary graft (LIMA). We carefully evaluate patients with single-vessel disease of the left anterior descending artery (LAD) and often prefer CABG given the durability of the LIMA compared with CTO PCI. However, we recommend CTO PCI to patients with shorter CTOs (to allow future LIMA touchdown when needed) and when PCI is unlikely to jeopardize significant branches (ie, as can occur with dissection re-entry). It is imperative to integrate the risks and benefits based on the degree of the patient's symptoms, anatomical factors, the operator's experience affecting the likelihood of successful procedure, the risk for complications, and patient preferences. (See  <a class="medical medical_review" href="/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a>.) </p><p>Among patients with multivessel disease and one or more CTOs, any of the following favor CABG [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Left main disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complex three-vessel disease, particularly in patients with insulin-requiring diabetes, severe left ventricular dysfunction, or chronic kidney disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An occluded proximal LAD that supplies a viable anterior wall that is not favorable for PCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple CTOs with a low anticipated rate of success.</p><p></p><p>Other patients can be managed by PCI with the goal being complete revascularization if possible. The nonoccluded vessels should be stented first (if indicated) if it is likely that ischemia in these territories may be responsible for the patient’s symptoms and there is a low anticipated rate of complications. In contrast, PCI should usually be performed first on the CTO if failed PCI of this lesion would lead to referral for CABG.</p><p class="headingAnchor" id="H25763584"><span class="h2">Informed consent</span><span class="headingEndMark"> — </span>We have an extensive discussion about risks and benefits of CTO PCI with the patient. In patients with a history of MI with low left ventricular ejection fraction (LVEF), we may consider viability study before CTO PCI. Ischemic mitral regurgitation is another indication that we sometimes consider (usually circumflex artery). We carefully review the films, and based on risk scores and our center's experience, we incorporate the likelihood of technical success and risk of complications in our discussions with the patient. We are careful that the patient is aware of the absence of demonstrated benefit of CTO PCI to improve mortality or MI rates, as many patients are motivated by a belief that an open vessel will lead to improved longevity. Based on our discussion, many patients opt to continue medical therapy alone, while others, typically the most symptomatic, opt to pursue CTO PCI.</p><p class="headingAnchor" id="H2459832433"><span class="h1">PROCEDURAL SUCCESS</span><span class="headingEndMark"> — </span>CTOs are challenging lesions to approach using percutaneous coronary intervention (PCI). The success rate, defined as achieving &lt;50 percent stenosis with TIMI 3 flow, has been very low (50 to 70 percent) compared with non-CTO PCI (approximately 95 percent) [<a href="#rid20">20-22</a>]. However, technical advances have increased the success rate without increasing rates of complications [<a href="#rid23">23</a>]. Studies report a success rate of 85 to 90 percent in experienced centers [<a href="#rid24">24-28</a>]. In contrast, a study including all operators independent of specific CTO expertise has reported a success rate of 59 percent [<a href="#rid23">23</a>]. For this reason, it is estimated that as few as 8 to 15 percent of patients with CTOs undergo PCI [<a href="#rid23">23,29-31</a>]. </p><p class="headingAnchor" id="H1193888410"><span class="h2">Predictors of technical failure</span><span class="headingEndMark"> — </span>Demographic and angiographic predictors of technical failure have been identified [<a href="#rid26">26,32</a>].</p><p>Demographic predictors include dialysis, a history of MI, prior revascularization (either coronary artery bypass graft surgery or PCI), prior stoke/transient ischemic attack, peripheral artery disease, heart failure, and age &gt;75 years [<a href="#rid33">33</a>]. Angiographic predictors include CTO length &gt;15 mm, saphenous vein graft, tortuous vessel, &gt;45 degree bending, moderate to severe calcification, ostial location of the CTO, and a blunt stump. A distal vessel that is &gt;2.0 mm in diameter, has little disease, and has no major branches generally facilitates CTO recanalization [<a href="#rid11">11</a>]. </p><p>In addition, low-volume operators (&lt;50 CTO PCI cases per year) have a lower procedural success rate as compared with high-volume operators [<a href="#rid27">27</a>]. High-volume centers have higher use of the retrograde approach with similar complication rates and higher success rates [<a href="#rid27">27,34</a>]. In a single-center study, the establishment of a coordinated CTO program with two operators scrubbed in each procedure and procedural protocols was followed by improvement in outcomes [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H1825929259"><span class="h2">Risk prediction scoring systems</span><span class="headingEndMark"> — </span>Many of the risk predictors discussed directly above have been integrated in several scores used to predict technical success. The following are two commonly used models:</p><p class="bulletIndent1"><span class="glyph">●</span>The Multicenter Chronic Total Occlusion Registry in Japan (J-CTO) is broadly used to describe CTO complexity and likelihood of procedural success [<a href="#rid36">36</a>]. This score, which predicts the likelihood of crossing the lesion within 30 minutes, includes five factors each worth one point when present: occlusion length ≥20 mm, blunt stump appearance of the proximal cap of the occlusion, calcification within the lesion segment, the presence of a &gt;45 degree bend within the CTO, and prior failed PCI attempt of the lesion. A J-CTO score of 0 is considered easy, score of 1 intermediate, 2 difficult, and ≥3 very difficult, with the probability of crossing within 30 minutes found to be 87.7, 67.1, 42.2, and 10 percent, respectively. The probability of a technically successful procedure was 97.8, 92.3, 88.4, and 73.3 percent, respectively [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS-CTO) score uses four independent variables to predict the likelihood of successful opening of a CTO: ambiguous proximal cap of the CTO (inability to discern precise location of vessel course), moderate or severe tortuosity, circumflex artery target CTO vessel, and lack of "interventional collaterals" to support a retrograde procedure [<a href="#rid37">37</a>]. The number of patients with a PROGRESS-CTO score ≥3 in the study was very low. Overall, the likelihood of success with a PROGRESS-CTO score of 0 was 91.3 percent, a score of 1 was 73.9 percent, a score of 2 was 56.5 percent, and a score of ≥3 was very low (&lt;4.3 percent). The PROGRESS-CTO score performed similarly to the J-CTO in predicting success, apart from lower complexity lesions where J-CTO had better discrimination.</p><p></p><p class="headingAnchor" id="H4286434899"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Successful percutaneous coronary intervention (PCI) of CTO is associated with improvement in anginal symptomatology. However, there does not appear to be improvement in rates of all-cause mortality, MI, stroke, and repeat revascularization. </p><p>Most studies evaluating the impact of PCI on outcomes among patients with CTO have been observational single-center or multicenter registries. In addition, a large proportion of the available outcome research studies were performed before several modern practice-changing techniques were available. Thus, the overall body of literature supporting CTO PCI does not provide strong evidence to inform the impact of modern CTO PCI on outcomes.</p><p class="headingAnchor" id="H277843176"><span class="h2">Angina relief and quality of life</span><span class="headingEndMark"> — </span>Multiple observational studies have demonstrated improvement in angina and quality of life in patients with successful CTO PCI [<a href="#rid38">38-40</a>]. The 2017 Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures (OPEN-CTO) Registry found that among the 1000 individuals undergoing CTO PCI, patients with successful CTO PCI showed significant improvement at one month in the Seattle Angina Questionnaire with quality-of-life scores of 10.8 points (p&lt;001) as compared with those patients who had an unsuccessful CTO PCI [<a href="#rid41">41</a>]. Similarly, there was a significantly higher reduction in mean Rose Dyspnea Scale score, which decreased (improved) more in patients with successful CTO PCI than in patients with unsuccessful procedures (p&lt;0.001) [<a href="#rid41">41</a>].</p><p>The EuroCTO Trial found improvement in the health status of patients with angina who underwent CTO PCI. In this trial, 396 individuals were randomly assigned (2:1) to PCI or optimal medical therapy (OMT) [<a href="#rid42">42</a>]. At 12 months, a greater improvement in the Seattle Angina Questionnaire subscale of angina frequency was observed with PCI than with OMT (p = 0.003). A second trial that randomly assigned 834 patients to OMT or CTO PCI showed no significant improvement in Seattle Angina Questionnaire subscale of angina frequency [<a href="#rid43">43</a>]. Limitations of this trial include the fact that half of the patients in each arm underwent non-CTO PCI after randomization, 20 percent of patients in the OMT arm underwent CTO PCI within three days of randomization, and the trial did not achieve expected power due to poor enrollment goals.</p><p>The COMET-CTO study of 100 patients randomly assigned to CTO PCI or OMT measured quality of life (assessed by Seattle angina questionnaire) at baseline and during a mean follow-up of 275 ± 88 days [<a href="#rid44">44</a>]. In patients assigned to CTO PCI, quality of life improved by over 20 points (scores range from 0 to 100), whereas for those assigned to OMT, there was no improvement.</p><p>Among 1000 consecutive patients who underwent CTO PCI in a 12-center registry, baseline quality of life (assessed by Seattle angina questionnaire) improved by an average of 36 at one year (scores range from 0 to 100) [<a href="#rid45">45</a>]. Similarly, an observational study in China showed that CTO PCI improved quality of life as assessed by a 12‐Item short‐form health survey questionnaire at one month and one year among patients of all ages, including those &gt;75 years of age [<a href="#rid46">46</a>]. </p><p class="headingAnchor" id="H4217062341"><span class="h2">Major adverse cardiac events (MACE)</span><span class="headingEndMark"> — </span>Elective CTO PCI using drug-eluting stents has not been shown to prevent all-cause mortality, myocardial infarction (MI), or stroke, though there may be a short-term benefit on reducing target lesion revascularization. This is not surprising given the absence of a clear benefit of elective PCI for MACE in non-CTO populations. (See  <a class="medical medical_review" href="/d/html/1557.html" rel="external">"Chronic coronary syndrome: Indications for revascularization", section on 'Patients with high-risk anatomy'</a>.)</p><p>A meta-analysis examined CTO PCI versus optimal medical therapy on all-cause mortality, cardiovascular mortality, MI, and target vessel revascularization outcomes [<a href="#rid47">47</a>]. The study included six randomized controlled trials of 1890 patients. Half of the lesions were in the right coronary artery with an average SYNTAX score of 21.4 ± 10. </p><p>This meta-analysis found that pooled rates of all-cause mortality, cardiovascular mortality, and MI were similar among patients who received CTO PCI compared with optimal medical therapy, although confidence intervals were wide and did not exclude an effect:</p><p class="bulletIndent1"><span class="glyph">●</span>All-cause mortality (one-year relative risk [RR] 1.70, 95% CI 0.50-5.80 and four-year RR 1.77, 95% CI 0.19-16.06).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular disease mortality (one-year RR 1.14, 95% CI 0.38-3.40 and four-year RR 2.05, 95% CI 0.8-5.28). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MI (one-year RR 1.01, 95% CI 0.43-2.36 and four-year RR 1.46, 95% CI 0.75-2.87).</p><p></p><p>However, the CTO PCI group had fewer target lesion revascularization at one but not at four years, compared with patients in the optimal medical therapy group (one-year RR 0.28, 95% CI 0.17-0.49) and (four-year RR 0.55 95% CI 0.28-1.09). Limitations of this analysis included relatively few one-year mortality and MI events and presence of high heterogeneity for some outcomes (eg, all-cause mortality and target vessel revascularization at four years).</p><p>Prior analyses of large registries and other observational data had provided mixed evidence in support of PCI; however, these are limited in their ability to infer a causal association between PCI and improved outcomes, given the inherent and unmeasured differences between patients more likely to have successful procedures versus those with failed procedures [<a href="#rid2">2,21,39,48-52</a>].</p><p class="headingAnchor" id="H794716341"><span class="h2">Left ventricular ejection fraction</span><span class="headingEndMark"> — </span>Small observational studies have suggested some improvement in LVEF after CTO PCI. A study from the Netherlands showed marginal improvement in ejection fraction from 60±9 to 63±11 percent by cardiac magnetic resonance imaging at five months after successful CTO PCI [<a href="#rid53">53</a>]. However, the majority of the patients had preserved LVEF prior to CTO PCI. Conversely, a trial including 72 patients with LVEF &lt;35 percent undergoing successful CTO PCI showed improvement in LVEF from 29.1±3.4 to 41.6±7.9 percent (p&lt;0.001) at six months [<a href="#rid54">54</a>].</p><p>Evaluating Xience and Left Ventricular Function in Percutaneous Coronary Intervention on Occlusions After ST-Elevation Myocardial Infarction (EXPLORE) was a randomized trial that evaluated the role of non-culprit CTO PCI within seven days of index presentation with STEMI versus no CTO PCI and showed no difference in LVEF or left ventricular end diastolic volume by cardiac magnetic resonance imaging after four months of index procedure [<a href="#rid55">55</a>]. However, the CTO PCI success rate in this study was low (77 percent) as compared with that reported in other centers, and sicker patients (shock, requiring implantable cardioverter-defibrillator, etc) were excluded.</p><p class="headingAnchor" id="H2468533966"><span class="h1">TECHNICAL ASPECTS OF CTO PCI</span><span class="headingEndMark"> — </span>Once the indications for CTO percutaneous coronary intervention (PCI) have been reviewed and the risk-benefit ratio has been discussed with the patient, there are several aspects of CTO PCI that differ from routine PCI. (See <a class="local">'Preprocedural steps'</a> above.)</p><p>First, extensive evaluation of the diagnostic coronary angiogram is encouraged in order to understand the characteristics of the proximal cap of the occlusion, the true occlusion length, the distal vessel quality and presence of important side branches, and the adequacy and course of collaterals. Second, two arterial access points are routinely used to enable simultaneous injections, one of the occluded vessel and the other of the collateral supplying vessel(s). Third, the operator should be facile with rapidly switching among several techniques and strategies [<a href="#rid10">10,11,56</a>].</p><p>In all cases, we use a microcatheter for optimal guidewire manipulation and exchange. </p><p>We prefer antegrade techniques when possible, given the higher likelihood of complications with retrograde procedures. Thus, we routinely start most cases with antegrade wire escalation and if we enter the subintimal space (dissection), we move to antegrade dissection re-entry (ADR) if the distal vessel is suitable for this approach and there is low risk of side branch compromise. Parallel wiring (adding a second antegrade wire) using a dual-lumen catheter is also often effective if the CTO is relatively short and straight. In patients who have good interventional collaterals, we would consider retrograde approach when antegrade wiring fails or if there is proximal cap ambiguity that might render an antegrade approach risky. Lastly, we would use a more aggressive form of subintimal tracking and reentry that creates a large dissection plane as a "bailout" strategy. In this case, we prefer not to deploy any stents given a high-likelihood of restenosis (approximately 50 percent) and thus we prefer a "re-look" coronary angiogram in six to eight weeks in which we usually stent once the artery has had time to heal. </p><p>For patients who have a bifurcation of the coronary artery very close to the distal cap and who have interventional collaterals, we would start the case with antegrade wire escalation (AWE) if the proximal cap is unambiguous and moves rapidly to retrograde approach if our antegrade wire goes into the subintimal space given that propagation of dissection past the distal cap would block flow to one of the branches of the bifurcation. Similarly, we would move faster to retrograde when the distal vessel is not a good target for re-entry (small or heavily calcified vessel).</p><p>In terms of access, our default strategy is to use a biradial approach to decrease the risk of vascular complications and bleeding (7F antegrade and 6F retrograde most often). </p><p class="headingAnchor" id="H3915802582"><span class="h2">Antegrade techniques</span><span class="headingEndMark"> — </span>Techniques that approach the CTO from the proximal side of the occlusion are considered to be "antegrade" techniques.</p><p class="bulletIndent1"><span class="glyph">●</span>AWE is usually the initial strategy for short CTOs in which the vessel course and origin of the occlusion are well defined. It consists of advancing wires with different degrees of stiffness, coating, and maneuverability through the true lumen of the vessel and then dilating with devices and balloons before proceeding with stenting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ADR includes several techniques in which wires and/or devices travel through the vessel wall (subintimal space) instead of the lumen and then re-access the true lumen past the occlusion with either specialized wiring technique (limited antegrade subintimal tracking) or specialized devices that enable true luminal reentry.</p><p></p><p class="headingAnchor" id="H3204570177"><span class="h2">Retrograde techniques</span><span class="headingEndMark"> — </span>Techniques that involve approaching the CTO from the distal end of the occlusion via collaterals or previously placed bypass grafts are considered to be "retrograde" techniques. Wiring through native vessel collaterals, commonly through the septal perforators but also through epicardial collaterals, typically involves delivering a soft wire through a collateral vessel to the target vessel distal to the total occlusion supported by a maneuverable microcatheter  (<a class="graphic graphic_diagnosticimage graphicRef120112" href="/d/graphic/120112.html" rel="external">image 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span>Retrograde wire escalation involves advancing a wire to the distal cap. Then a sequential advancement of wires with different degrees of stiffness through the true lumen of the vessel can be performed similarly to the antegrade wire escalation. Retrograde true luminal wiring, particularly in short occlusions, may be more straightforward than antegrade luminal wiring when the proximal cap of the occlusion is ambiguous or severely calcified.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retrograde dissection reentry is used in complex lesions when retrograde wires are not able to be advanced across the occlusion in the true luminal space. The most common retrograde techniques that involve subintimal passage of wires are variants of what is termed "controlled antegrade and retrograde tracking" (CART). CART procedures involve inflating a balloon to enlarge the false luminal area to allow for a common space for antegrade and retrograde wires to meet, and to create a passageway between the false and true lumen. Most commonly, "reverse CART" is performed in which a balloon is inserted over a wire that passes from the proximal true lumen and into the subintimal space within the CTO and is inflated. Subsequently, a retrograde wire in the common subintimal space is then advanced following the pathway created by the antegrade balloon inflation, and ultimately into the antegrade guide or guide extension catheter. The retrograde wire can be externalized out of the body through the antegrade guide, and PCI can be performed over this wire. Retrograde techniques can improve the success rate of CTO programs and operators but are associated with a higher rate of complications [<a href="#rid57">57,58</a>].</p><p></p><p class="headingAnchor" id="H2672902833"><span class="h1">COMPLICATIONS AND OUTCOMES</span><span class="headingEndMark"> — </span>The complications of CTO percutaneous coronary intervention (PCI) are similar to those of routine PCI but occur more frequently. The higher complication rate should factor into the decision of whether to proceed with PCI. (See <a class="local">'Preprocedural steps'</a> above and  <a class="medical medical_review" href="/d/html/1562.html" rel="external">"Periprocedural complications of percutaneous coronary intervention"</a>.)</p><p>A large analysis of the National Cardiovascular Data Registry in the United States showed higher in-hospital major adverse cardiovascular event (MACE) frequency (1.6 versus 0.8 percent; p&lt;0.001), mortality (0.4 versus 0.3 percent; p&lt;0.001), stroke (0.1 versus 0.1 percent; p = 0.045), tamponade (0.3 versus 0.1 percent; p&lt;0.001), MI (2.7 versus 1.9 percent; p&lt;0.001), and need for packed red blood cell transfusion (2.7 versus 1.9 percent; p&lt;0.001) in 22,365 patients who underwent CTO PCI compared with 572,145 patients who underwent non-CTO PCI [<a href="#rid23">23</a>]. </p><p>In a meta-analysis of 65 contemporary studies with 18,061 patients, the pooled estimated rate was MACE 3.1 percent, death 0.1 percent, need for emergent coronary artery bypass graft surgery 0.1 percent, stroke 0.1 percent, type 4 MI 2.8 percent, coronary perforation 3.2 percent, tamponade 0.5 percent, and contrast-induced nephropathy 1.2 percent [<a href="#rid58">58</a>]. Failed CTO PCI carries a higher complication rate [<a href="#rid23">23</a>]. Most studies have not included consecutive CTO PCI patients or had systematic and adjudicated capture of complications, and may thus underestimate the true risks of CTO PCI. </p><p>The OPEN-CTO Registry, which included 1000 consecutive patients (not highly selected) from 12 high-volume CTO PCI centers found the following in-hospital complication rates: MACE 7 percent, death 0.9 percent, MI 2.6 percent, stroke 0 percent, significant Ellis grade ≥3 perforation (3.3 percent), bleeding requiring treatment (0.3 percent), and acute kidney injury (0.7 percent) [<a href="#rid41">41</a>].</p><p>On average, contrast volume is greater and fluoroscopy time is longer with PCI of a CTO than a non-CTO lesion.</p><p class="headingAnchor" id="H1002006910"><span class="h1">LONG-TERM OUTCOMES, INCLUDING NEED FOR REPEAT VASCULARIZATION</span><span class="headingEndMark"> — </span>Most studies examining the long-term patency of CTO percutaneous coronary intervention (PCI) were performed with first-generation drug-eluting stents (DES) [<a href="#rid59">59-62</a>] . A study including 1226 consecutive patients who underwent CTO PCI at three high-volume PCI centers showed a target vessel revascularization (TVR) rate of 17 percent five years after implantation of a DES (most of them first generation) [<a href="#rid61">61</a>]. A study that used more modern DES platforms that included 223 patients undergoing CTO PCI with antegrade techniques showed TVR rates between 3.1 and 15.5 percent at 24 months (depending on the crossing technique used) [<a href="#rid63">63</a>]. Data from randomized trials have shown similar revascularization rates. For example, in a study of 1184 consecutive patients who underwent CTO PCI and were randomized to a DES versus bare metal stent (BMS), the five-year TVR-free survival rate was 81.6 and 73.5 percent (log-rank p&lt;0.001) in the two groups, respectively [<a href="#rid60">60</a>]; similarly, in a cohort including 991 procedures in three large-volume centers using modern DES, the TVR was 9.4 percent with a median follow-up of 1.2 years [<a href="#rid64">64</a>]. </p><p>Long-term outcomes after CTO PCI were compared with non-CTO PCI in the National Cardiovascular Data Registry. CTO PCI was associated with a slightly higher risk of long-term repeat revascularization compared with non-CTO PCI (adjusted hazard ratio [aHR] 1.09; 95% CI 1.05-1.13). However, compared with high-risk non-CTO PCIs (including saphenous vein graft and unprotected left main PCI or PCI requiring atherectomy), CTO PCI was associated with a slightly lower risk of long-term MACE (aHR 0.87; 95% CI 0.84-0.90) and readmission (aHR 0.87; 95% CI 0.84-0.90) [<a href="#rid65">65</a>].</p><p>There appear to be differences in TVR rates based on the different CTO PCI techniques. A study with 223 patients undergoing CTO PCI using antegrade dissection re-entry (see <a class="local">'Antegrade techniques'</a> above) techniques in four high-volume CTO PCI centers described a TVR as low as 3.1 percent using modern reentry devices [<a href="#rid63">63</a>] while other studies using different techniques have reported a TVR of 52.4 percent [<a href="#rid66">66</a>]. This wide variability in TVR is a reflection of the differences in CTO PCI techniques and differences in procedural characteristics, and points to the need for large population-based studies evaluating long-term patency of CTO PCI.</p><p class="headingAnchor" id="H1564300834"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>We generally use the following sequential approach to CTO PCI:</p><p class="bulletIndent1"><span class="glyph">●</span>We recommend that in most cases, CTO PCI should not be done in the same procedure as the first diagnostic angiogram, that is, ad hoc CTO PCI should be avoided. This allows time for a careful discussion of potential risks and benefits of the procedure with the patient, and dedicated time to review the anatomy and potential approach in detail. (See <a class="local">'Complications and outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We carefully review the patient's history and angiogram to make sure that PCI is a reasonable choice. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We allow the patient to participate in decision making. (See <a class="local">'Informed consent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In our institutions, we refer the patient to interventionalists who are highly skilled in CTO PCI (a CTO team).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We choose a technical approach that includes multiple contingencies if the initial selected approach fails. (See <a class="local">'Technical aspects of CTO PCI'</a> above.)</p><p></p><p class="headingAnchor" id="H893314170"><span class="h1">RECOMMENDATIONS OF OTHERS</span><span class="headingEndMark"> — </span>The American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions give a weak recommendation to proceed with CTO percutaneous coronary intervention (PCI) in patients with a clinical indication and suitable anatomy when performed by an experienced operator [<a href="#rid67">67</a>]. </p><p>The 2018 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guideline on myocardial revascularization states that indications for CTO PCI are similar to those for non-CTO [<a href="#rid68">68</a>]. </p><p class="headingAnchor" id="H2959824319"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119298.html" rel="external">"Society guideline links: Coronary artery bypass graft surgery"</a>.)</p><p class="headingAnchor" id="H2472935899"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>– CTO is highly prevalent in patients with symptomatic coronary artery disease. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– CTO percutaneous coronary intervention (PCI) should be considered in patients with disabling angina despite treatment with optimal medical therapy in whom there is a reasonable chance of technical success with an acceptable risk. Complications during CTO PCI, though not prohibitive, occur more frequently than in routine PCI. (See <a class="local">'Indications'</a> above and <a class="local">'Complications and outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– Successful CTO PCI is associated with improvement in anginal symptomatology. However, there does not appear to be improvement in rates of all-cause mortality, myocardial infarction (MI), stroke, and long-term repeat revascularization. There may be a short-term benefit for revascularization in the first year following CTO PCI. (See <a class="local">'Outcomes'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technical aspects </strong>– We prefer to start with antegrade techniques when possible, given the higher likelihood of complications with retrograde procedures. However, operators performing CTOs should feel comfortable with switching quickly between approaches to maximize the probability of success and reducing the risk of complications. (See <a class="local">'Technical aspects of CTO PCI'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stone GW, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005; 112:2364.</a></li><li><a class="nounderline abstract_t">Ivanhoe RJ, Weintraub WS, Douglas JS Jr, et al. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up. Circulation 1992; 85:106.</a></li><li><a class="nounderline abstract_t">Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation 2021; 143:479.</a></li><li><a class="nounderline abstract_t">Christofferson RD, Lehmann KG, Martin GV, et al. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol 2005; 95:1088.</a></li><li><a class="nounderline abstract_t">Fefer P, Knudtson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol 2012; 59:991.</a></li><li><a class="nounderline abstract_t">Jeroudi OM, Alomar ME, Michael TT, et al. Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. Catheter Cardiovasc Interv 2014; 84:637.</a></li><li><a class="nounderline abstract_t">Werner GS, Gitt AK, Zeymer U, et al. Chronic total coronary occlusions in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice. Clin Res Cardiol 2009; 98:435.</a></li><li><a class="nounderline abstract_t">Tsai TT, Stanislawski MA, Shunk KA, et al. Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights From the VA CART Program. JACC Cardiovasc Interv 2017; 10:866.</a></li><li><a class="nounderline abstract_t">Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J 2012; 33:768.</a></li><li><a class="nounderline abstract_t">Tajti P, Karmpaliotis D, Alaswad K, et al. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry. JACC Cardiovasc Interv 2018; 11:1325.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation 2019; 140:420.</a></li><li><a class="nounderline abstract_t">Kawashima H, Takahashi K, Ono M, et al. Mortality 10 years after percutaneous or surgical revascularization in patients with total coronary artery occlusions. J Am Coll Cardiol 2021; :529.</a></li><li><a class="nounderline abstract_t">Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113:2406.</a></li><li><a class="nounderline abstract_t">Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009; 2:17.</a></li><li><a class="nounderline abstract_t">Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation 2012; 125:2613.</a></li><li><a class="nounderline abstract_t">Claessen BE, van der Schaaf RJ, Verouden NJ, et al. Evaluation of the effect of a concurrent chronic total occlusion on long-term mortality and left ventricular function in patients after primary percutaneous coronary intervention. JACC Cardiovasc Interv 2009; 2:1128.</a></li><li><a class="nounderline abstract_t">Azzalini L, Jolicoeur EM, Pighi M, et al. Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. Am J Cardiol 2016; 118:1128.</a></li><li><a class="nounderline abstract_t">Tomasello SD, Boukhris M, Giubilato S, et al. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. Eur Heart J 2015; 36:3189.</a></li><li><a class="nounderline abstract_t">Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112:2530.</a></li><li><a class="nounderline abstract_t">Noguchi T, Miyazaki MD S, Morii I, et al. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. Catheter Cardiovasc Interv 2000; 49:258.</a></li><li><a class="nounderline abstract_t">Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001; 38:409.</a></li><li><a class="nounderline abstract_t">Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008; 1:10.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Banerjee S, Karmpaliotis D, et al. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv 2015; 8:245.</a></li><li><a class="nounderline abstract_t">Christopoulos G, Karmpaliotis D, Alaswad K, et al. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. Int J Cardiol 2015; 198:222.</a></li><li><a class="nounderline abstract_t">Maeremans J, Walsh S, Knaapen P, et al. The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe: The RECHARGE Registry. J Am Coll Cardiol 2016; 68:1958.</a></li><li><a class="nounderline abstract_t">Galassi AR, Boukhris M, Azzarelli S, et al. Percutaneous Coronary Revascularization for Chronic Total Occlusions: A Novel Predictive Score of Technical Failure Using Advanced Technologies. JACC Cardiovasc Interv 2016; 9:911.</a></li><li><a class="nounderline abstract_t">Habara M, Tsuchikane E, Muramatsu T, et al. Comparison of percutaneous coronary intervention for chronic total occlusion outcome according to operator experience from the Japanese retrograde summit registry. Catheter Cardiovasc Interv 2016; 87:1027.</a></li><li><a class="nounderline abstract_t">Wilson WM, Walsh SJ, Yan AT, et al. Hybrid approach improves success of chronic total occlusion angioplasty. Heart 2016; 102:1486.</a></li><li><a class="nounderline abstract_t">Bagnall A, Spyridopoulos I. The evidence base for revascularisation of chronic total occlusions. Curr Cardiol Rev 2014; 10:88.</a></li><li><a class="nounderline abstract_t">Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002; 39:1096.</a></li><li><a class="nounderline abstract_t">Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 2000; 102:2945.</a></li><li><a class="nounderline abstract_t">Alessandrino G, Chevalier B, Lefèvre T, et al. A Clinical and Angiographic Scoring System to Predict the Probability of Successful First-Attempt Percutaneous Coronary Intervention in Patients With Total Chronic Coronary Occlusion. JACC Cardiovasc Interv 2015; 8:1540.</a></li><li><a class="nounderline abstract_t">Wang N, Fulcher J, Abeysuriya N, et al. Predictors of successful chronic total occlusion percutaneous coronary interventions: a systematic review and meta-analysis. Heart 2018; 104:517.</a></li><li><a class="nounderline abstract_t">Thompson CA, Jayne JE, Robb JF, et al. Retrograde techniques and the impact of operator volume on percutaneous intervention for coronary chronic total occlusions an early U.S. experience. JACC Cardiovasc Interv 2009; 2:834.</a></li><li><a class="nounderline abstract_t">Karmpaliotis D, Lembo N, Kalynych A, et al. Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes. Catheter Cardiovasc Interv 2013; 82:1.</a></li><li><a class="nounderline abstract_t">Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. JACC Cardiovasc Interv 2011; 4:213.</a></li><li><a class="nounderline abstract_t">Christopoulos G, Kandzari DE, Yeh RW, et al. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. JACC Cardiovasc Interv 2016; 9:1.</a></li><li><a class="nounderline abstract_t">Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes 2010; 3:284.</a></li><li><a class="nounderline abstract_t">Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. Am Heart J 2010; 160:179.</a></li><li><a class="nounderline abstract_t">Kucukseymen S, Iannaccone M, Grantham JA, et al. Association of Successful Percutaneous Revascularization of Chronic Total Occlusions With Quality of Life: A Systematic Review and Meta-Analysis. JAMA Netw Open 2023; 6:e2324522.</a></li><li><a class="nounderline abstract_t">Sapontis J, Salisbury AC, Yeh RW, et al. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv 2017; 10:1523.</a></li><li><a class="nounderline abstract_t">Werner GS, Martin-Yuste V, Hildick-Smith D, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018; 39:2484.</a></li><li><a class="nounderline abstract_t">Lee SW, Lee PH, Ahn JM, et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. Circulation 2019; 139:1674.</a></li><li><a class="nounderline abstract_t">Juricic SA, Tesic MB, Galassi AR, et al. Randomized Controlled Comparison of Optimal Medical Therapy with Percutaneous Recanalization of Chronic Total Occlusion (COMET-CTO). Int Heart J 2021; 62:16.</a></li><li><a class="nounderline abstract_t">Hirai T, Grantham JA, Sapontis J, et al. Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina. Circ Cardiovasc Interv 2019; 12:e007558.</a></li><li><a class="nounderline abstract_t">Zhao S, Wang J, Chen Y, et al. Improvement of Symptoms and Quality of Life After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Elderly Patients. J Am Heart Assoc 2023; 12:e029034.</a></li><li><a class="nounderline abstract_t">Krittanawong C, Virk HH, Mhanna M, et al. Meta-Analysis of Percutaneous Coronary Intervention of Chronic Total Occlusions. Am J Cardiol 2021; 159:148.</a></li><li><a class="nounderline abstract_t">Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002. Eur Heart J 2005; 26:2630.</a></li><li><a class="nounderline abstract_t">Lee PH, Lee SW, Park HS, et al. Successful Recanalization of Native Coronary Chronic Total Occlusion Is Not Associated With Improved Long-Term Survival. JACC Cardiovasc Interv 2016; 9:530.</a></li><li><a class="nounderline abstract_t">George S, Cockburn J, Clayton TC, et al. Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database. J Am Coll Cardiol 2014; 64:235.</a></li><li><a class="nounderline abstract_t">Yamamoto E, Natsuaki M, Morimoto T, et al. Long-term outcomes after percutaneous coronary intervention for chronic total occlusion (from the CREDO-Kyoto registry cohort-2). Am J Cardiol 2013; 112:767.</a></li><li><a class="nounderline abstract_t">Strauss BH, Knudtson ML, Cheema AN, et al. Canadian Multicenter Chronic Total Occlusion Registry: Ten-Year Follow-Up Results of Chronic Total Occlusion Revascularization. Circ Cardiovasc Interv 2021; 14:e010546.</a></li><li><a class="nounderline abstract_t">Kirschbaum SW, Baks T, van den Ent M, et al. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. Am J Cardiol 2008; 101:179.</a></li><li><a class="nounderline abstract_t">Galassi AR, Boukhris M, Toma A, et al. Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction. JACC Cardiovasc Interv 2017; 10:2158.</a></li><li><a class="nounderline abstract_t">Henriques JP, Hoebers LP, Råmunddal T, et al. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. J Am Coll Cardiol 2016; 68:1622.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Grantham JA, Rinfret S, et al. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. JACC Cardiovasc Interv 2012; 5:367.</a></li><li><a class="nounderline abstract_t">Galassi AR, Sianos G, Werner GS, et al. Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry. J Am Coll Cardiol 2015; 65:2388.</a></li><li><a class="nounderline abstract_t">Patel VG, Brayton KM, Tamayo A, et al. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv 2013; 6:128.</a></li><li><a class="nounderline abstract_t">Rahel BM, Laarman GJ, Kelder JC, et al. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J 2009; 157:149.</a></li><li><a class="nounderline abstract_t">Han YL, Zhang J, Li Y, et al. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions. Chin Med J (Engl) 2009; 122:643.</a></li><li><a class="nounderline abstract_t">Mehran R, Claessen BE, Godino C, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv 2011; 4:952.</a></li><li><a class="nounderline abstract_t">De Felice F, Fiorilli R, Parma A, et al. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. JACC Cardiovasc Interv 2009; 2:1260.</a></li><li><a class="nounderline abstract_t">Azzalini L, Dautov R, Brilakis ES, et al. Procedural and longer-term outcomes of wire- versus device-based antegrade dissection and re-entry techniques for the percutaneous revascularization of coronary chronic total occlusions. Int J Cardiol 2017; 231:78.</a></li><li><a class="nounderline abstract_t">Azzalini L, Dautov R, Ojeda S, et al. Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion. JACC Cardiovasc Interv 2017; 10:892.</a></li><li><a class="nounderline abstract_t">Tamez H, Secemsky EA, Valsdottir LR, et al. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention 2021; 17:e380.</a></li><li><a class="nounderline abstract_t">Colombo A, Mikhail GW, Michev I, et al. Treating chronic total occlusions using subintimal tracking and reentry: the STAR technique. Catheter Cardiovasc Interv 2005; 64:407.</a></li><li><a class="nounderline abstract_t">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.</a></li><li><a class="nounderline abstract_t">Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2019; 55:4.</a></li></ol></div><div id="topicVersionRevision">Topic 115590 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216980" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728439" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33523728" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842978" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of chronic total coronary occlusion on treatment strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22402070" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142769" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19294443" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic total coronary occlusions in patients with stable angina pectoris: impact on therapy and outcome in present day clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28473108" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights From the VA CART Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240495" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706508" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356129" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mortality 10 years after percutaneous or surgical revascularization in patients with total coronary artery occlusions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702469" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463393" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22550156" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926056" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evaluation of the effect of a concurrent chronic total occlusion on long-term mortality and left ventricular function in patients after primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27561190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26333367" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230504" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700054" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11499731" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031650" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25700746" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26189193" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27788851" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe: The RECHARGE Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085580" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Percutaneous Coronary Revascularization for Chronic Total Occlusions: A Novel Predictive Score of Technical Failure Using Advanced Technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26719060" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of percutaneous coronary intervention for chronic total occlusion outcome according to operator experience from the Japanese retrograde summit registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27164918" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hybrid approach improves success of chronic total occlusion angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24694105" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The evidence base for revascularisation of chronic total occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923031" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113044" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493246" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A Clinical and Angiographic Scoring System to Predict the Probability of Successful First-Attempt Percutaneous Coronary Intervention in Patients With Total Chronic Coronary Occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28986404" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of successful chronic total occlusion percutaneous coronary interventions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19778771" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Retrograde techniques and the impact of operator volume on percutaneous intervention for coronary chronic total occlusions an early U.S. experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576529" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349461" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26762904" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388873" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20598990" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37471086" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association of Successful Percutaneous Revascularization of Chronic Total Occlusions With Quality of Life: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797429" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29722796" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30813758" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33518655" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized Controlled Comparison of Optimal Medical Therapy with Percutaneous Recanalization of Chronic Total Occlusion (COMET-CTO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30871356" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37026557" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Improvement of Symptoms and Quality of Life After Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Elderly Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34489086" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Meta-Analysis of Percutaneous Coronary Intervention of Chronic Total Occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16183693" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947387" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Successful Recanalization of Native Coronary Chronic Total Occlusion Is Not Associated With Improved Long-Term Survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034057" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735646" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Long-term outcomes after percutaneous coronary intervention for chronic total occlusion (from the CREDO-Kyoto registry cohort-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34932391" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Canadian Multicenter Chronic Total Occlusion Registry: Ten-Year Follow-Up Results of Chronic Total Occlusion Revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178403" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29055762" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27712774" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516392" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A percutaneous treatment algorithm for crossing coronary chronic total occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26046732" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23352817" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081412" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19323927" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21939934" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Long-term outcome of percutaneous coronary intervention for chronic total occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20129553" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27887799" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Procedural and longer-term outcomes of wire- versus device-based antegrade dissection and re-entry techniques for the percutaneous revascularization of coronary chronic total occlusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412256" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32863243" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15789384" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treating chronic total occlusions using subintimal tracking and reentry: the STAR technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22064601" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165632" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 2018 ESC/EACTS Guidelines on myocardial revascularization.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
